COMMUNIQUÉS West-GlobeNewswire

Psychemedics Unveils Inaugural Insights Report: Revealing Drug Trends Through Hair Testing
21/06/2024
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a [...]
Sharecare enters into definitive agreement to be acquired by Altaris
21/06/2024
Sharecare shareholders to receive $1.43 per share in cash Transaction will deliver significant immediate cash value to stockholders upon closing, best positions Sharecare to continue to deliver exceptional service to [...]
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
21/06/2024
Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting Halle (Saale) / Munich, Germany, June 21, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon, or the Company [...]
Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
21/06/2024
– Collaboration advancing Palisade Bio’s precision medicine approach through access to cutting-edge expertise and tools in bioinformatics – Candidate PDE4-related biomarkers overlapping with UC pathophysiology have been [...]
Starton Therapeutics Announces 100% Partial Response or Better in Multiple Myeloma Patients in Interim, Top-line Data from STAR-LLD Phase 1b Clinical Trial
21/06/2024
100% of patients enrolled achieved a partial response or better Milder and less frequent drug-related adverse events were observed compared to those associated with Revlimid ® No grade 3 or greater adverse events in [...]
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
21/06/2024
Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and Potential Launch in Early [...]
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
21/06/2024
Webinar will include discussion of APR-1051 in context of emerging WEE1 inhibitor landscape DOYLESTOWN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a [...]
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
21/06/2024
Patient Enrollment in Pivotal STRIVE-ON Phase 3 Safety Trial for GTX-104 On-Track for Potential NDA Submission in 1H Calendar 2025 Projected Cash Runway into Second Calendar Quarter 2026 PRINCETON, N.J., June 21, 2024 ( [...]
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
21/06/2024
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics- [...]
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
21/06/2024
CNM-Au8 demonstrated neuroprotective effects in an in vitro model of Rett Syndrome, a rare pediatric neurodevelopmental disease CNM-Au8 also demonstrated rescue of mitochondrial deficits in induced astrocytes derived [...]
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21/06/2024
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the Biennial International [...]
Atlantic International Corp. Acquires Lyneer Staffing Solutions
21/06/2024
Creates National Strategic Staffing, Outsourced Services and Workforce Solutions Company with Over $400 Million in Revenues for the 12 Months Ended December 31, 2023 and Adjusted EBITDA of $5.4 Million ENGLEWOOD CLIFFS [...]
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
21/06/2024
• Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial • DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen [...]
Trading by management and close relations of management
21/06/2024
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of [...]
Major shareholder announcement
21/06/2024
June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary [...]
Medigene to Present at the Cell and Gene Therapy In-Depth Focus Summit 2024
21/06/2024
Planegg/Martinsried, June 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
21/06/2024
Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee Paris, June 21, 2024 . Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President [...]
Communiqué de presse : Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi
21/06/2024
Audrey Duval Derveloy nommée Directrice Affaires Corporate Groupe, membre du Comité exécutif de Sanofi Paris, le 21 juin 2024 . Audrey Duval Derveloy, leader chevronnée du secteur de la santé et Présidente de Sanofi [...]
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
21/06/2024
Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category ‘ [...]

Pages